Solta Medical, Inc. Sustainability Profile
Solta Medical, Inc., a prominent player in the medical aesthetics industry, is headquartered in the United States. Founded in 2006, the company has established itself as a leader in innovative technologies for non-invasive and minimally invasive aesthetic treatments. With a focus on skin rejuvenation, body contouring, and hair removal, Solta Medical offers a range of unique products, including the well-regarded Thermage and Fraxel systems, which are known for their efficacy and patient satisfaction. Operating primarily in North America and expanding into international markets, Solta Medical has achieved significant milestones, including numerous industry awards and recognitions for its cutting-edge solutions. The company’s commitment to research and development ensures it remains at the forefront of aesthetic advancements, solidifying its market position as a trusted provider in the field.
DitchCarbon Score
How does Solta Medical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Solta Medical, Inc.'s score of 40 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Solta Medical, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Bausch Health Companies Inc., which means that any emissions data or climate commitments may be inherited from its parent organisation. As of now, Solta Medical has not established specific reduction targets or initiatives, nor does it participate in the Science Based Targets initiative (SBTi) or disclose information through the Carbon Disclosure Project (CDP). The absence of documented climate pledges or reduction initiatives indicates that the company may still be in the early stages of developing its climate strategy. Given the lack of specific emissions data and reduction commitments, it is essential for Solta Medical to align with industry standards and best practices in climate action, potentially leveraging the frameworks and targets set by Bausch Health Companies Inc. to enhance its sustainability efforts in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 46,686,000 | 00,000,000 |
| Scope 2 | 50,513,000 | 00,000,000 |
| Scope 3 | 19,260,000 | 00,000,000 |
How Carbon Intensive is Solta Medical, Inc.'s Industry?
How Carbon Intensive is Solta Medical, Inc.'s Location?
Solta Medical, Inc.'s Scope 3 Categories Breakdown
Solta Medical, Inc.'s Scope 3 emissions, which increased by 41% last year and increased by approximately 41% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 21% of total emissions under the GHG Protocol, with "Waste Generated in Operations" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Solta Medical, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Solta Medical, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
